ATE469168T1 - Peptide zur transglutaminase-hemmung - Google Patents

Peptide zur transglutaminase-hemmung

Info

Publication number
ATE469168T1
ATE469168T1 AT06799169T AT06799169T ATE469168T1 AT E469168 T1 ATE469168 T1 AT E469168T1 AT 06799169 T AT06799169 T AT 06799169T AT 06799169 T AT06799169 T AT 06799169T AT E469168 T1 ATE469168 T1 AT E469168T1
Authority
AT
Austria
Prior art keywords
transglutaminase
cancers
peptides
disclosed
inflammatory diseases
Prior art date
Application number
AT06799169T
Other languages
English (en)
Inventor
Soo Youl Kim
In Hoo Kim
Sung Soo Park
Original Assignee
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct filed Critical Nat Cancer Ct
Application granted granted Critical
Publication of ATE469168T1 publication Critical patent/ATE469168T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
AT06799169T 2005-12-16 2006-10-11 Peptide zur transglutaminase-hemmung ATE469168T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050124420 2005-12-16
PCT/KR2006/004089 WO2007069817A1 (en) 2005-12-16 2006-10-11 Peptides for inhibiting transglutaminase

Publications (1)

Publication Number Publication Date
ATE469168T1 true ATE469168T1 (de) 2010-06-15

Family

ID=38163103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06799169T ATE469168T1 (de) 2005-12-16 2006-10-11 Peptide zur transglutaminase-hemmung

Country Status (8)

Country Link
US (1) US8754033B2 (de)
EP (1) EP1866329B1 (de)
JP (1) JP5006336B2 (de)
KR (1) KR100838715B1 (de)
CN (1) CN101180311A (de)
AT (1) ATE469168T1 (de)
DE (1) DE602006014519D1 (de)
WO (1) WO2007069817A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
AU2010225460B2 (en) * 2009-03-19 2014-05-01 Queensland University Of Technology Targets for growth factor signalling and methods of therapy
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
GB201318182D0 (en) * 2013-10-14 2013-11-27 Univ Nottingham Trent Inhibitor peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2859270B2 (ja) * 1987-06-11 1999-02-17 旭光学工業株式会社 カメラの視線方向検出装置
DE69232629T2 (de) 1992-03-23 2003-01-30 University Of Manitoba, Winnipeg Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
DE69943222D1 (de) 1998-12-10 2011-04-07 Signal Pharm Llc Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
EP1235936A2 (de) * 1999-11-30 2002-09-04 Curagen Corporation Nukleinsäure, die einzelnukleotid-polymorphismen enthalten und verfahren zur deren verwendung
WO2002027031A2 (en) * 2000-09-28 2002-04-04 Cellomics, Inc. Methods and reagents for live-cell gene expression quantification
EP1499885B1 (de) * 2001-08-01 2009-10-21 Cellomics, Inc. Neue fusionsproteine und molekulare bindungsassays
US20090131270A1 (en) * 2004-08-02 2009-05-21 Cellumen, Inc.A Corporation Methods for the detection of molecular interactions within cells

Also Published As

Publication number Publication date
EP1866329A4 (de) 2008-05-21
CN101180311A (zh) 2008-05-14
JP5006336B2 (ja) 2012-08-22
KR100838715B1 (ko) 2008-06-16
US20090197812A1 (en) 2009-08-06
WO2007069817A1 (en) 2007-06-21
DE602006014519D1 (de) 2010-07-08
JP2009519323A (ja) 2009-05-14
EP1866329B1 (de) 2010-05-26
EP1866329A1 (de) 2007-12-19
KR20070064379A (ko) 2007-06-20
US8754033B2 (en) 2014-06-17

Similar Documents

Publication Publication Date Title
IL194843A0 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
EP2607348A3 (de) Hemmer des plasminogen-aktivator-inhibitors 1
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
WO2006091395A3 (en) Inhibitors of akt activity
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
DE602007005120D1 (de) 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist
TW200736253A (en) Pyridopyrazine derivatives and their use
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
EA201070611A1 (ru) Ингибиторы человеческой фосфатидилинозитол-3-киназы дельта
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
ATE520668T1 (de) Sigmarezeptor-inhibitoren
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
WO2007121124A3 (en) Hcv inhibitors comprising beta amino acids and their uses
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
WO2008153318A3 (en) Transglutaminase inhibitor comprising chlorogenic acid and a method for producing thereof
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties